Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?

被引:141
作者
Ahmed, Hashim Uddin [1 ,2 ]
Arya, Manit [4 ]
Freeman, Alex [3 ]
Emberton, Mark [1 ,2 ]
机构
[1] UCL, Div Surg & Intervent Sci, London W1P 7NN, England
[2] Univ Coll London Hosp NHS Fdn Trust, Dept Urol, London, England
[3] Univ Coll London Hosp NHS Fdn Trust, Dept Histopathol, London, England
[4] Queen Mary Univ London, Barts Canc Inst, Barts & London Sch Med & Dent, London, England
基金
英国医学研究理事会; 英国惠康基金; 美国国家卫生研究院;
关键词
CHEMOKINE RECEPTOR CXCR4; TUMOR VOLUME; RADICAL PROSTATECTOMY; ACTIVE SURVEILLANCE; INTERNATIONAL-SOCIETY; CLINICAL-SIGNIFICANCE; HISTOLOGICAL GRADE; GLEASON SCORE; COPY NUMBER; ADENOCARCINOMA;
D O I
10.1016/S1470-2045(12)70388-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer is generally multifocal and consists of a dominant focus-measured by tumour volume and deemed the index lesion-and one or more separate, secondary tumour foci of smaller volume. Much laboratory and clinical evidence has shown that we need to rethink how we regard low-grade and low-volume prostate lesions. In this Personal View, we discuss why small, low-grade Gleason pattern prostate lesions, which are currently designated as prostate cancer, could be regarded as non-malignant. These lesions either do not meet the criteria of the hallmarks of cancer or robust evidence that they do so is absent, by contrast with large lesions with a high Gleason grade, which seem to cause most metastatic disease.
引用
收藏
页码:E509 / E517
页数:9
相关论文
共 77 条
[1]   Focal Therapy for Localized Prostate Cancer: A Phase I/II Trial [J].
Ahmed, H. U. ;
Freeman, A. ;
Kirkham, A. ;
Sahu, M. ;
Scott, R. ;
Allen, C. ;
Van der Meulen, J. ;
Emberton, M. .
JOURNAL OF UROLOGY, 2011, 185 (04) :1246-1254
[2]   Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study [J].
Ahmed, Hashim U. ;
Hindley, Richard G. ;
Dickinson, Louise ;
Freeman, Alex ;
Kirkham, Alex P. ;
Sahu, Mahua ;
Scott, Rebecca ;
Allen, Clare ;
Van der Meulen, Jan ;
Emberton, Mark .
LANCET ONCOLOGY, 2012, 13 (06) :622-632
[3]   Is it time to consider a role for MRI before prostate biopsy? [J].
Ahmed, Hashim U. ;
Kirkham, Alex ;
Arya, Manit ;
Illing, Rowland ;
Freeman, Alex ;
Allen, Clare ;
Emberton, Mark .
NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (04) :197-206
[4]   The Index Lesion and the Origin of Prostate Cancer [J].
Ahmed, Hashim Uddin .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (17) :1704-1706
[5]   Prostate cancer and the Will Rogers phenomenon [J].
Albertsen, PC ;
Hanley, JA ;
Barrows, GH ;
Penson, DF ;
Kowalczyk, PDH ;
Sanders, MM ;
Fine, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1248-1253
[6]   National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009 [J].
Allegra, Carmen J. ;
Aberle, Denise R. ;
Ganschow, Pamela ;
Hahn, Stephen M. ;
Lee, Clara N. ;
Millon-Underwood, Sandra ;
Pike, Malcolm C. ;
Reed, Susan D. ;
Saftlas, Audrey F. ;
Scarvalone, Susan A. ;
Schwartz, Arnold M. ;
Slomski, Carol ;
Yothers, Greg ;
Zon, Robin .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (03) :161-169
[7]   Focal Cryotherapy for Clinically Unilateral, Low-Intermediate Risk Prostate Cancer in 73 Men with a Median Follow-Up of 3.7 Years [J].
Bahn, Duke ;
Abreu, Andre Luis de Castro ;
Gill, Inderbir S. ;
Hung, Andrew J. ;
Silverman, Paul ;
Gross, Mitchell E. ;
Lieskovsky, Gary ;
Ukimura, Osamu .
EUROPEAN UROLOGY, 2012, 62 (01) :55-63
[8]   Identifying Candidates for Active Surveillance: An Evaluation of the Repeat Biopsy Strategy for Men with Favorable Risk Prostate Cancer [J].
Barzell, Winston E. ;
Melamed, Myron R. ;
Cathcart, Paul ;
Moore, Caroline M. ;
Ahmed, Hashim U. ;
Emberton, Mark .
JOURNAL OF UROLOGY, 2012, 188 (03) :762-767
[9]   ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality [J].
Bismar, Tarek A. ;
Dolph, Michael ;
Teng, Liang-Hong ;
Liu, Shuhong ;
Donnelly, Bryan .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (04) :538-546
[10]   Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening [J].
Black, WC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1280-1282